Omilancor mitigates the senescence of nucleus pulposus cells induced by DDP through targeting MAP2K6.
Aging (Albany NY)
; 16(6): 5050-5064, 2024 03 20.
Article
en En
| MEDLINE
| ID: mdl-38517363
ABSTRACT
PURPOSE:
This study explores the potential of Omilancor in treating Intervertebral Disc Degeneration (IDD) through MAP2K6 targeting.METHODS:
We analyzed mRNA microarray datasets to pinpoint MAP2K6 as a key regulator implicated in IDD progression. Follow-up studies demonstrated that cisplatin (DDP) could prompt cellular senescence in vitro by upregulating MAP2K6 expression. Through molecular docking and other analyses, we identified Omilancor as a compound capable of binding to MAP2K6. This interaction effectively impeded the cellular senescence induced by DDP.RESULTS:
We further showed that administration of Omilancor could significantly alleviate the degeneration of IVDs in annulus fibrosus puncture-induced rat model.CONCLUSIONS:
Omilancor shows promise as a treatment for IDD by targeting MAP2K6-mediated cellular senescence.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Degeneración del Disco Intervertebral
/
Anillo Fibroso
/
Núcleo Pulposo
Límite:
Animals
Idioma:
En
Revista:
Aging (Albany NY)
Asunto de la revista:
GERIATRIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Estados Unidos